Taiwan
World
China
Life
AI & Semiconductor
Business
Taiwan
World
China
Life
AI & Semiconductor
Business
Taiwan
World
China
Life
AI & Semiconductor
Business
Home
ASC30_39 FDC
#
ASC30_39 FDC
About 1 search results
Sort by Date
Business
PR Newswire
Ascletis Submits IND Application to the U.S. FDA for ASC30_39 FDC, a Potentially First-in-Class Oral Small Molecule Fixed-Dose Combination of GLP-1R Agonist and Selective Amylin Receptor Agonist, for the Treatment of Obesity
-
PR Newswire
2026-11-11 17:10
ASC30_39 FDC
Ascletis
Obesity